Thus, the latter can deliver circZFR to the recipient HCC cells, inhibit the STAT3/NF-κB signaling pathway, and facilitate HCC cells’ proliferation and chemoresistance to cisplatin [123]. This evidence concerns the gene STAT3 and hepatocellular carcinoma.